Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | MECP2 | P51608 | 1/20 | 0.44 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433480 | 1.00 | MEN1 (0.49) | MEN1ALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL27402049 | 0.78 | MDM2 (0.45) | MEN1KDM4EMAPTKMT2AMAOA | |
| SCHEMBL29840687 | 0.77 | RAB9A (0.47) | KDM4EHPGDMETAP2NPC1RAB9A | |
| SCHEMBL29840619 | 0.77 | PLCG2 (0.57) | MEN1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL9362727 | 0.77 | NPC1 (0.44) | MEN1KDM4EMAPTKMT2ANPC1 | |
| SCHEMBL25078680 | 0.77 | RAB9A (0.47) | KDM4EHPGDMETAP2NPC1RAB9A | |
| SCHEMBL15859222 | 0.77 | HSD17B1 (0.55) | METAP2NPC1RAB9ACYP3A4 | |
| SCHEMBL27880965 | 0.77 | KARS1 (0.43) | NPC1RAB9A | |
| SCHEMBL390107 | 0.75 | CYP1A2 (0.49) | MEN1ALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL139209 | 0.74 | MDM2 (0.51) | MEN1ALDH1A1KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107636871-A | Substitution isoxazole for lithium battery | 国轩高科美国研究院 | 2018-01-26 | — | — | CN | claimed |
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| CN-107636871-A | Substitution isoxazole for lithium battery | 国轩高科美国研究院 | 2018-01-26 | — | — | CN | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| EP-1613312-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA A RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2008-02-20 | — | — | EP | disclosed |
| EP-1613312-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA A RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2008-02-20 | — | — | EP | disclosed |
| US-20060148856-A1 | Benzimidazole derivatives and their use for modulating the gabaa receptor complex | ANIONA APS (DK) | 2006-07-06 | — | — | US | disclosed |
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1613312-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA sb A /sb RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| EP-1613618-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087690-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087690-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087137-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087137-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | MEN1 1305/4885ALDH1A1 238/4885KDM4E 2609/4885 |
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | GABRB2, GABRB1, GABRB3 | MEN1 4428/4885ALDH1A1 477/4885KDM4E 1815/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MEN1 544/4885ALDH1A1 4333/4885KDM4E 1662/4885 |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | MEN1 1305/4885ALDH1A1 238/4885KDM4E 2609/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MEN1 636/4885ALDH1A1 4184/4885KDM4E 1645/4885 |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | MEN1 1305/4885ALDH1A1 238/4885KDM4E 2609/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MEN1 636/4885ALDH1A1 4184/4885KDM4E 1645/4885 |
| US-20060148856-A1 | Benzimidazole derivatives and their use for modulating the gabaa receptor complex | GABRB2, GABRB1, GABRB3 | MEN1 4166/4885ALDH1A1 312/4885KDM4E 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.